CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • United States
    Entity • The products and services listed on this website are not available in this location.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Trade AstraZeneca PLC - GBP - AZNl CFD

    117.28
    0.43%
    0.32
    Low: 115.38
    High: 117.3
    Market Trading Hours* (UTC) Opens on Monday at 07:00

    Mon - Fri: 07:00 - 11:00 11:03 - 15:30

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.32
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.023178 %
    Charges from borrowed part ($-0.93)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		-0.023178%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.00126 %
    Charges from borrowed part ($0.05)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		0.00126%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency GBP
    Margin 20%
    Stock exchange United Kingdom of Great Britain and Northern Ireland
    Commission on trade 0%

    *Information provided by Capital.com

    AstraZeneca PLC ESG Risk Ratings

    High Medium Low Negligible

    ‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

    More ESG coverage

    Key Stats
    Prev. Close* 116.78
    Open* 115.68
    1-Year Change* 11.07%
    Day's Range* 115.38 - 117.3
    52 wk Range 93.99-128.29
    Average Volume (10 days) 1.40M
    Average Volume (3 months) 32.52M
    Market Cap 183.20B
    P/E Ratio 48.79
    Shares Outstanding 1.55B
    Revenue 35.22B
    EPS 2.42
    Dividend (Yield %) 2.03609
    Beta 0.26
    Next Earnings Date Jul 28, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Jun 2, 2023 117.28 1.62 1.40% 115.66 117.40 115.30
    May 31, 2023 116.78 2.22 1.94% 114.56 117.54 114.30
    May 30, 2023 113.22 -4.28 -3.64% 117.50 118.28 113.22
    May 26, 2023 116.62 -0.10 -0.09% 116.72 118.18 116.10
    May 25, 2023 116.08 -0.70 -0.60% 116.78 118.08 115.64
    May 24, 2023 116.34 -2.04 -1.72% 118.38 119.14 116.34
    May 23, 2023 119.79 0.42 0.35% 119.37 121.71 118.86
    May 22, 2023 119.77 0.22 0.18% 119.55 120.95 119.55
    May 19, 2023 120.21 0.62 0.52% 119.59 120.61 119.22
    May 18, 2023 119.60 0.11 0.09% 119.49 120.83 119.49
    May 17, 2023 118.62 -2.43 -2.01% 121.05 121.69 118.50
    May 16, 2023 120.31 1.10 0.92% 119.21 120.89 119.21
    May 15, 2023 119.80 -0.21 -0.17% 120.01 120.49 119.58
    May 12, 2023 119.72 0.56 0.47% 119.16 120.75 119.06
    May 11, 2023 119.12 0.44 0.37% 118.68 119.87 118.52
    May 10, 2023 117.98 0.00 0.00% 117.98 118.64 116.92
    May 9, 2023 118.74 1.22 1.04% 117.52 119.28 117.52
    May 5, 2023 118.92 0.90 0.76% 118.02 118.94 116.98
    May 4, 2023 118.34 0.02 0.02% 118.32 118.66 117.42
    May 3, 2023 118.68 0.24 0.20% 118.44 118.92 117.66

    AstraZeneca PLC - GBP Events

    Time (UTC) Country Event
    Monday, June 5, 2023

    Time (UTC)

    23:00

    Country

    GB

    Event

    AstraZeneca PLC at ASCO Investor Meeting (Virtual)
    AstraZeneca PLC at ASCO Investor Meeting (Virtual)

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 44351 37417 26617 24384 22090
    Revenue 44351 37417 26617 24384 22090
    Cost of Revenue, Total 8649 9542 5270 4824 4246
    Gross Profit 35702 27875 21347 19560 17844
    Total Operating Expense 40594 36361 21455 21460 18703
    Selling/General/Admin. Expenses, Total 13512 11519 9338 8964 8479
    Research & Development 9612 8519 6094 5320 5266
    Depreciation / Amortization 4094 3044 1897 1812 1945
    Unusual Expense (Income) 4820 3846 -763 863 -953
    Other Operating Expenses, Total -93 -109 -381 -323 -280
    Operating Income 3757 1056 5162 2924 3387
    Interest Income (Expense), Net Non-Operating -815 -819 -716 -766 -775
    Other, Net -441 -502 -530 -610 -619
    Net Income Before Taxes 2501 -265 3916 1548 1993
    Net Income After Taxes 3293 115 3144 1227 2050
    Minority Interest -5 -3 52 108 105
    Net Income Before Extra. Items 3288 112 3196 1335 2155
    Net Income 3288 112 3196 1335 2155
    Income Available to Common Excl. Extra. Items 3288 112 3196 1335 2155
    Income Available to Common Incl. Extra. Items 3288 112 3196 1335 2155
    Dilution Adjustment 0 0
    Diluted Net Income 3288 112 3196 1335 2155
    Diluted Weighted Average Shares 1560 1427 1313 1301 1267
    Diluted EPS Excluding Extraordinary Items 2.10769 0.07849 2.43412 1.02613 1.70087
    Dividends per Share - Common Stock Primary Issue 2.89361 2.84245 2.83031 2.89446 2.74532
    Diluted Normalized EPS 3.8859 2.22705 1.88804 1.48501 0.85399
    Interest Expense (Income) - Net Operating 0 0
    Total Extraordinary Items
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total revenue 10879 11207 10982 10771 11390
    Revenue 10879 11207 10982 10771 11390
    Cost of Revenue, Total 2053 2417 2118 1904 2279
    Gross Profit 8826 8790 8864 8867 9111
    Total Operating Expense 8330 10113 9737 10232 10512
    Selling/General/Admin. Expenses, Total 3196 3469 3353 3633 3057
    Research & Development 2299 2638 2357 2431 2186
    Depreciation / Amortization 954 1034 979 983 1098
    Unusual Expense (Income) 230 331 1002 1298 1953
    Other Operating Expenses, Total -402 224 -72 -17 -61
    Operating Income 2549 1094 1245 539 878
    Interest Income (Expense), Net Non-Operating -287 -316 -323 -292 -325
    Net Income Before Taxes 2262 778 922 247 553
    Net Income After Taxes 1804 902 1642 360 388
    Minority Interest -1 -1 -2 0 -2
    Net Income Before Extra. Items 1803 901 1640 360 386
    Net Income 1803 901 1640 360 386
    Income Available to Common Excl. Extra. Items 1803 901 1640 360 386
    Income Available to Common Incl. Extra. Items 1803 901 1640 360 386
    Dilution Adjustment
    Diluted Net Income 1803 901 1640 360 386
    Diluted Weighted Average Shares 1560 1560 1559 1560 1561
    Diluted EPS Excluding Extraordinary Items 1.15577 0.57756 1.05196 0.23077 0.24728
    Dividends per Share - Common Stock Primary Issue 0 1.9694 0 0.93017 0
    Diluted Normalized EPS 1.27335 0.70833 0.99743 0.80833 1.24792
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 22593 26244 19544 15563 15591
    Cash and Short Term Investments 6405 6398 7992 6218 5680
    Cash 1411 1461 1182 755 893
    Cash & Equivalents 4755 4868 6650 4614 3938
    Short Term Investments 239 69 160 849 849
    Total Receivables, Net 9923 8795 5651 5181 4345
    Accounts Receivable - Trade, Net 7508 6324 3956 3813 2995
    Total Inventory 4699 8983 4024 3193 2890
    Prepaid Expenses 1329 1512 1735 865 1436
    Other Current Assets, Total 237 556 142 106 1240
    Total Assets 96483 105363 66729 61377 60651
    Property/Plant/Equipment, Total - Net 9449 10171 8917 8335 7421
    Property/Plant/Equipment, Total - Gross 17192 18495 17110 15852 14639
    Accumulated Depreciation, Total -7743 -8324 -8193 -7517 -7218
    Goodwill, Net 19820 19997 11845 11668 11707
    Intangibles, Net 39307 42387 20947 20833 21959
    Long Term Investments 1142 1237 1147 1459 922
    Note Receivable - Long Term 592 504 325 348 515
    Other Long Term Assets, Total 3580 4823 4004 3171 2536
    Total Current Liabilities 26293 22594 20307 18117 16292
    Accounts Payable 2550 2824 2350 1774 1720
    Accrued Expenses 8303 8079 4994 5085 5148
    Notes Payable/Short Term Debt 261 294 370 154 160
    Current Port. of LT Debt/Capital Leases 5281 1599 2016 1856 1594
    Other Current Liabilities, Total 9898 9798 10577 9248 7670
    Total Liabilities 59446 66095 51107 48250 48183
    Total Long Term Debt 23690 28888 17994 16217 17359
    Long Term Debt 22965 28134 17505 15730 17359
    Capital Lease Obligations 725 754 489 487 0
    Deferred Income Tax 2944 6206 2918 2490 3286
    Minority Interest 21 19 16 1469 1576
    Other Liabilities, Total 6498 8388 9872 9957 9670
    Total Equity 37037 39268 15622 13127 12468
    Common Stock 387 387 328 328 317
    Additional Paid-In Capital 35155 35126 7971 7941 4427
    Retained Earnings (Accumulated Deficit) 1495 3755 7323 4858 7724
    Total Liabilities & Shareholders’ Equity 96483 105363 66729 61377 60651
    Total Common Shares Outstanding 1549.8 1549.4 1312.67 1312.14 1267.04
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 22266 22593 20224 20917 22647
    Cash and Short Term Investments 6462 6405 4898 4887 5823
    Cash & Equivalents 6232 6166 4458 4817 5762
    Short Term Investments 230 239 440 70 61
    Total Receivables, Net 10797 11252 10061 9612 9050
    Accounts Receivable - Trade, Net 10289 10521 9336 8908 8683
    Total Inventory 4967 4699 5078 6220 7624
    Other Current Assets, Total 40 237 187 198 150
    Total Assets 96687 96483 94185 96579 100273
    Property/Plant/Equipment, Total - Net 9599 9449 9227 9627 10015
    Goodwill, Net 20001 19820 19707 19821 19963
    Intangibles, Net 39291 39307 39585 39900 41265
    Long Term Investments 1234 1142 1102 1180 1237
    Note Receivable - Long Term 682 835 792 881 864
    Other Long Term Assets, Total 3614 3337 3548 4253 4282
    Total Current Liabilities 24860 26293 24850 21815 22740
    Payable/Accrued 19210 19040 17694 17821 17864
    Notes Payable/Short Term Debt 568 261 584 636 724
    Current Port. of LT Debt/Capital Leases 3289 5281 5034 1746 1570
    Other Current Liabilities, Total 1793 1711 1538 1612 2582
    Total Liabilities 60898 59446 59051 60647 63933
    Total Long Term Debt 27646 23690 23681 27146 28805
    Long Term Debt 26916 22965 23013 26461 28081
    Capital Lease Obligations 730 725 668 685 724
    Deferred Income Tax 2795 2944 3479 5275 5626
    Minority Interest 22 21 20 19 19
    Other Liabilities, Total 5575 6498 7021 6392 6743
    Total Equity 35789 37037 35134 35932 36340
    Common Stock 387 387 387 387 387
    Additional Paid-In Capital 35159 35155 35137 35134 35131
    Retained Earnings (Accumulated Deficit) 243 1495 -390 411 822
    Total Liabilities & Shareholders’ Equity 96687 96483 94185 96579 100273
    Total Common Shares Outstanding 1549.85 1549.8 1549.51 1549.48 1549.45
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 2501 -265 3916 1548 1993
    Cash From Operating Activities 9808 5963 4799 2969 2618
    Cash From Operating Activities 5480 6530 3149 3762 3753
    Non-Cash Items 542 141 -332 -103 -1276
    Cash Taxes Paid 1623 1743 1562 1118 537
    Cash Interest Paid 849 721 733 774 676
    Changes in Working Capital 1285 -443 -1934 -2238 -1852
    Cash From Investing Activities -2960 -11058 -285 -657 963
    Capital Expenditures -2571 -2200 -2606 -2460 -1371
    Other Investing Cash Flow Items, Total -389 -8858 2321 1803 2334
    Cash From Financing Activities -6823 3649 -2203 -1765 -2044
    Financing Cash Flow Items -1047 -178 -101 4 -67
    Total Cash Dividends Paid -4364 -3856 -3572 -3592 -3484
    Issuance (Retirement) of Stock, Net 29 29 30 3525 34
    Issuance (Retirement) of Debt, Net -1441 7654 1440 -1702 1473
    Foreign Exchange Effects -80 -62 12 5 -38
    Net Change in Cash -55 -1508 2323 552 1499
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 2262 2501 1723 800 553
    Cash From Operating Activities 3133 9808 7410 4480 3232
    Cash From Operating Activities 1502 5480 4000 2666 1309
    Non-Cash Items -391 542 172 15 -12
    Cash Taxes Paid 225 1623 1335 1006 228
    Cash Interest Paid 257 849 608 386 194
    Changes in Working Capital -240 1285 1515 999 1382
    Cash From Investing Activities -1246 -2960 -2711 -968 -168
    Capital Expenditures -1470 -2571 -2017 -906 -363
    Other Investing Cash Flow Items, Total 224 -389 -694 -62 195
    Cash From Financing Activities -2031 -6823 -6465 -5035 -3740
    Financing Cash Flow Items -840 -1047 -1047 -997 -997
    Total Cash Dividends Paid -3047 -4364 -4364 -2971 -2971
    Issuance (Retirement) of Stock, Net 4 29 11 8 5
    Issuance (Retirement) of Debt, Net 1852 -1441 -1065 -1075 223
    Foreign Exchange Effects -11 -80 -86 -35 -9
    Net Change in Cash -155 -55 -1852 -1558 -685
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    BlackRock Institutional Trust Company, N.A. Investment Advisor 6.5098 100893184 1200 2023-01-31 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 4.1999 65092368 768 2023-01-31 LOW
    Capital Research Global Investors Investment Advisor 4.1199 63852512 752 2023-01-31 LOW
    Investor AB Private Equity 3.3299 51608948 608 2023-01-31 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.8464 44114976 -1215991 2022-12-14 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 2.2269 34514808 15209 2023-05-01 LOW
    Capital World Investors Investment Advisor 1.7648 27351981 2675871 2022-12-14 LOW
    BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 1.2141 18816198 280706 2023-05-01 LOW
    BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 1.1273 17471628 -78807 2023-05-01 LOW
    GQG Partners, LLC Investment Advisor 1.0697 16579162 1036509 2022-12-14 MED
    Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.9835 15243057 -36818 2023-05-01 LOW
    State Street Global Advisors (UK) Ltd. Investment Advisor/Hedge Fund 0.6302 9767199 -6522 2023-05-01 LOW
    Nuveen LLC Pension Fund 0.6158 9543355 495683 2022-12-14 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5411 8386244 -95567 2022-12-14 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.4985 7725827 -10523 2023-05-01 LOW
    Handelsbanken Kapitalförvaltning AB Investment Advisor/Hedge Fund 0.4931 7642032 181760 2023-04-30 LOW
    Aviva Investors Global Services Limited Investment Advisor/Hedge Fund 0.4919 7623953 -442236 2023-05-01 LOW
    M & G Investment Management Ltd. Investment Advisor 0.4722 7318503 -220395 2023-05-01 LOW
    Fidelity Management & Research Company LLC Investment Advisor 0.4707 7294740 0 2023-05-01 LOW
    BlackRock Investment Management, LLC Investment Advisor/Hedge Fund 0.4379 6787247 -85660 2023-03-31 LOW

    Why choose Capital.com? Our numbers speak for themselves.

    Capital.com Group

    535K+

    Traders

    87K+

    Active clients monthly

    $113M+

    Monthly investing volume

    $64M+

    Withdrawn each month

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Profit/Loss

    AstraZeneca - GBP Company profile

    About AstraZeneca plc

    AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.

    Industry: Pharmaceuticals (NEC)

    1 Francis Crick Avenue
    CAMBRIDGE
    CAMBRIDGESHIRE CB2 0AA
    GB

    Income Statement

    • Annual
    • Quarterly

    News

    Turkish lira on top of USA national currency, top view of mixed American dollars banknotes. TRY and USA paper money. Lira and US dollars exchange rate

    USD/TRY forecast: Turkish lira under pressure from high inflation and low rates

    We look at some of the latest USD/TRY predictions as the Turkish lira hits record lows.

    17:07, 1 June 2023
    Nvidia HQ in Santa Clara, California

    Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?

    Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?

    07:46, 31 May 2023
    Alphabet Inc and Google logos on a smartphone screen

    Google stock forecast 2023-2025

    What is the outlook for the tech giant, following a tumultuous 2022?

    18:02, 30 May 2023
    Benjamin Franklin’s face on a $100 bill

    USD forecast: DXY slides in risk-off market sentiment

    The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.

    16:10, 24 May 2023
    Oil wells pictured in an oil field, silhouetted against clouds

    Oil price forecast: Will WTI and Brent regain momentum in 2023?

    Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.

    11:38, 22 May 2023
    businessman using a mobile phone to check stock market data

    Weekly Roundup: Tech stocks lead the way

    US stocks push higher as risk appetite surges despite the uncertainty

    13:39, 19 May 2023
    Japanese yen currency

    USD/JPY continues to build higher towards 138

    USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher

    11:50, 17 May 2023

    People also watch

    Oil - Crude

    71.98 Price
    +2.450% 1D Chg, %
    Long position overnight fee -0.0201%
    Short position overnight fee -0.0018%
    Overnight fee time 21:00 (UTC)
    Spread 0.04

    Gold

    1,948.36 Price
    -1.480% 1D Chg, %
    Long position overnight fee -0.0185%
    Short position overnight fee 0.0103%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    US100

    14,557.80 Price
    +0.640% 1D Chg, %
    Long position overnight fee -0.0255%
    Short position overnight fee 0.0032%
    Overnight fee time 21:00 (UTC)
    Spread 3.0

    XRP/USD

    0.53 Price
    -0.350% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.00395

    Still looking for a broker you can trust?

    Join the 535.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading